EMERGENT BIOSOLUTIONS INC. Deferred Tax Assets, Deferred Income
EMERGENT BIOSOLUTIONS INC. (EBS) had Deferred Tax Assets, Deferred Income of $0 as of 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2024-03-08
- 2023-12-31: Deferred Tax Assets, Deferred Income $0.00.
- 2022-12-31: Deferred Tax Assets, Deferred Income $2.00M.
- 2021-12-31: Deferred Tax Assets, Deferred Income $400.00K.
- 2020-12-31: Deferred Tax Assets, Deferred Income $26.20M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-08 |
| 2022-12-31 | $2.00M 10-K · filed 2024-03-08 |
| 2021-12-31 | $400.00K 10-K/A · filed 2023-12-11 |
| 2020-12-31 | $26.20M 10-K · filed 2022-02-25 |
| 2019-12-31 | $18.10M 10-K · filed 2021-02-19 |
| 2018-12-31 | $11.60M 10-K · filed 2020-02-25 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-22 |
| 2014-12-31 | $244.00K 10-K · filed 2015-03-09 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-09 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-10 |
| 2011-12-31 | $485.00K 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |